Alkahest, Inc.

Rutgers, The State University of New Jersey

Leland Stanford Junior University

The United States Government As Represented by the Department of Veterans Affairs

Steven P Braithwaite

S Sakura Minami

Ian Gallager

Eva Czirr

Nina Huber

Michael Voronkov

Karoly Nikolich

M Maral Mouradian

Joseph McCracken

Anton Wyss-Coray

Saul A Villeda

Meghan Kerrisk Campbell

Sam Jackson

Mary Maral Mouradian

Vu Dang

Joe McCracken

David Bell

Joseph Mccracken

Joe Mccracken

Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as cognitive disorders. The methods relate to a regimen of pulsed dosing of blood plasma or blood plasma fractions.

Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products

Methods of improving neurodegenerative disease with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in cognition, motor, or other neurodegenerative-affected function. Cognitive and motor diseases upon which the methods of the invention can improve cognition include Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, myotonic dystrophy, vascular dementia, progressive supranuclear palsy.

Methods and compositions for treating aging-associated impairments using CCR3-inhibitors

The invention relates to treating individuals with cancer by using blood plasma or blood plasma fractions as treatment.

Blood plasma and plasma fractions as therapy for tumor growth and progression

Methods and compositions are provided for screening candidate compositions for activity with respect to treatment of aging-associated conditions, e.g., cognitive impairment conditions or age-related dementia. Aspects of the methods include administering a human blood product comprising plasma, to an immunocompromised animal, e.g., a mouse or a rat, and measuring the effect of the product on an endpoint, e.g., neurogenesis, locomotor activity, anxiety, spatial memory, and hippocampus-dependent memory.

Methods for screening human blood products comprising plasma using immunocompromised rodent models

Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action &#x3bc;-opioid receptor antagonist/&#x3ba;-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a &#x3bc;-opioid receptor antagonist or prodrug thereof, and a &#x3ba;-opioid receptor agonist or prodrug thereof can be administered, either together or separately.

Method of treating dyskinesia

Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Blood plasma fractions as a treatment for aging-associated cognitive disorders

Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action &#x3bc;-opioid receptor antagonist/&#x3ba;-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.

Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.

Growing community of inventors

Redwood City, CA, United States of America

Steven P Braithwaite